Channel 04 · Dose context
BPC-157 Dosage in Preclinical Studies: What Was Administered, to Which Species, by Which Route
Animal-model figures and routes, read as study-administered values — never as human directions. No validated human dose exists, and the short half-life means the dose is not the disciplining datum here.
BPC-157 dosage ranges in preclinical studies
BPC-157 dosage in the published literature is expressed per body weight in animals, and this console reports it as exactly that — studied figures, not guidance. Rodent studies commonly used doses around 10 microg/kg and 10 ng/kg, and some tendon work went as low as 10 pg per rat [1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg in rats, where the higher doses produced an ulcer-formation inhibition ratio of 45.7-65.6% [4].
Human pilot figures are minimal and belong to specific study contexts, not to any protocol: a two-person intravenous safety pilot used 10 mg then 20 mg by infusion [14], and an interstitial-cystitis pilot used a single 10 mg dose intravesically [11]. No controlled human trial has defined an effective or safe dose, so there is no validated human dose to report. Every figure on this page is framed as "studied at X in [species]," which is the only framing the evidence supports.
How long should I stay on BPC-157?
There is no validated human duration or cycle. Animal studies use widely varying schedules by model and route, and no controlled human trial has defined a treatment length. Because BPC-157 is not an approved drug and human data are minimal, the literature supports describing doses "studied at X in [species]" rather than recommending any human duration.
Routes studied in the literature (intraperitoneal, intramuscular, local)
The BPC-157 injection routes in the underlying animal work are several, and the console lists them as the methods used, not as administration instructions. Intraperitoneal injection is the most common route in rodent studies [1][7]. Intramuscular and local or intra-lesional routes appear across the tissue-repair models, and in the foundational gastric-ulcer study intramuscular delivery outperformed intragastric [4]. The human pilots used intravenous [14], intravesical [11], and intra-articular [10] routes within their specific study designs.
The pharmacokinetic context bounds all of this: intramuscular bioavailability was reported around 14-19% in rats and 45-51% in dogs, with an elimination half-life under 30 minutes [2]. The console states routes and bioavailability as characterized facts; it does not translate any of them into a human injection practice.
Can BPC-157 be taken orally?
BPC-157 is termed a stable gastric pentadecapeptide because it is reported to be stable in human gastric juice, which is the rationale behind oral and peroral interest, and intragastric dosing has been used in animal studies [4]. Despite this, formal human oral pharmacokinetics are not established, so oral bioavailability and effective oral dosing in humans remain unproven.
Oral BPC-157: the stable-gastric-peptide claim and the PK gap
The question that drives this section — does oral BPC-157 work — has a split answer that the console keeps split rather than averaging.
Does oral BPC-157 work?
In animal models, intragastric and peroral BPC-157 has produced effects, consistent with its reported gastric stability [4]. But there is no established human oral pharmacokinetic profile and no controlled human trial of oral dosing, so whether oral BPC-157 works in people is not demonstrated by the published evidence. In the foundational rat ulcer study, intramuscular delivery outperformed intragastric [4], a detail worth holding against the assumption that oral is simply equivalent.
The "stable gastric pentadecapeptide" descriptor is doing specific work: it says the molecule resists breakdown in gastric juice, which is the precondition for oral interest but not the same as proven oral absorption into the circulation [4]. The honest console reading is that the stability claim is established and the human oral PK is not — those are two different facts, and the gap between them is exactly where the evidence stops. The disciplining datum remains the pharmacokinetics and half-life: under 30 minutes, parent peptide, fast clearance [2].